文献速递浆细胞疾病淋巴瘤

NKTR-255(一种新型聚合物偶联人IL-15)改善多发性骨髓瘤中NK细胞功能

Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15.
PubMed 文献 · Blood Adv · 2023-01-01

本研究评估研究性药物NKTR-255(IL-15受体激动剂)激活IL-15通路并刺激NK细胞对抗多发性骨髓瘤(MM)细胞的能力。体外实验中,NKTR-255使MM患者外周血单核细胞来源的NK细胞偏向活化表型,并增强其对MM细胞系和原代MM细胞的脱颗粒、细胞因子释放及抗肿瘤细胞毒性。在H929 MM细胞皮下移植的完全人源化免疫健全小鼠中,每周注射NKTR-255较安慰剂增加外周血循环NK细胞数量并延缓肿瘤生长;NKTR-255与抗CD38抗体达雷妥尤单抗联合在体外和体内均有效。

要点

  • NKTR-255使MM患者NK细胞活化受体表达增加,偏向活化表型。
  • NKTR-255增强NK细胞对MM细胞系和原代MM细胞的脱颗粒、细胞因子释放及细胞毒性。
  • NKTR-255联合达雷妥尤单抗在体外和体内均有效抗MM细胞。

核心结论

  • 数据提示NKTR-255对诱导NK细胞抗MM细胞功能有显著影响,具有重要转化意义。

研究设计与样本

  • 体外研究评估NKTR-255对MM患者外周血单核细胞来源NK细胞的活化表型及功能影响。
  • 体内研究使用H929 MM细胞皮下移植的完全人源化免疫健全小鼠,比较每周注射NKTR-255与安慰剂的效应。
  • 体外和体内评估NKTR-255联合抗CD38抗体达雷妥尤单抗对MM细胞的疗效。

主要发现

  • NKTR-255孵育使MM患者来源NK细胞表面活化受体表达增加,偏向活化表型。
  • NK细胞暴露于MM细胞系和原代MM细胞时,NKTR-255增强脱颗粒、细胞因子释放和抗肿瘤细胞毒性。
  • 与安慰剂相比,每周注射NKTR-255增加H929皮下移植完全人源化免疫健全小鼠外周血循环NK细胞数量并延缓肿瘤生长。
  • NKTR-255联合达雷妥尤单抗在体外和体内均有效对抗MM细胞。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is characterized by an immunosuppressive microenvironment that enables tumor development. One of the mechanisms of immune evasion used by MM cells is the inhibition of natural killer (NK) cell effector functions; thus, the restoration of NK cell antitumor activity represents a key goal to increase tumor cell recognition, avoid tumor escape and potentially enhancing the effect of other drugs. In this study, we evaluated the ability of the investigational medicine NKTR-255, an IL-15 receptor agonist, to engage the IL-15 pathway and stimulate NK cells against MM cells. We observed that incubation with NKTR-255 was able to tilt the balance toward an activated phenotype in NK cells isolated from peripheral blood mononuclear cells of patients with MM, with increased expression of activating receptors on the surface of treated NK cells. This resulted in an enhanced degranulation, cytokine release, and anti-tumor cytotoxicity when the NK cells were exposed to both MM cell lines and primary MM cells. We further evaluated the in vivo effect of NKTR-255 in fully humanized immunocompetent mice subcutaneously engrafted with H929 MM cells. Compared with placebo, weekly injection of the mice with NKTR-255 increased the number of circulating NK cells in peripheral blood and delayed tumor growth. Finally, we observed that combination of NKTR-255 with the anti-CD38 antibody, daratumumab, was effective against MM cells in vitro and in vivo. Taken together, our data suggest a significant impact of NKTR-255 in inducing NK cell function against MM cells with important translational implications.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Fernandez RA, Mayoral JE, Pierre-Louis L, et al. Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15. Blood Adv. 2023. PMID: 35882498. doi:10.1182/bloodadvances.2022007985

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。